EUDA Health Holdings Ltd (EUDAW) Research & Development (2022 - 2023)
EUDA Health Holdings' (EUDAW) quarterly Research & Development came in at -$27299.0 in Q2 2023, down 104.21% year-on-year from $647854.0 in Q2 2022, and down 106.74% on a QoQ basis from $404771.0 in Q1 2023.
EUDA Health Holdings Ltd (EUDAW) Research & Development (2022 - 2023) Analysis & Trends
EUDA Health Holdings (EUDAW) has 2 years of Research & Development data on file, last reported at -$27299.0 in Q2 2023.
- On a quarterly basis, Research & Development fell 104.21% year-over-year to -$27299.0 in Q2 2023; TTM through Jun 2023 was $1.0 million, a N/A change from a year earlier, with the FY2025 full-year figure at $1.3 million, up 888.54% from the prior year.
- Research & Development for Q2 2023 stood at -$27299.0, down from $404771.0 in the prior quarter.
- Over the last five years, Research & Development for EUDAW reached as high as $647854.0 in Q2 2022 and fell as low as -$27299.0 in Q2 2023.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | -27,299.00 |
| Mar 31, 2023 | 404,771.00 |
| Jun 30, 2022 | 647,854.00 |
| Mar 31, 2022 | 2,946.00 |